Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation
2020 · Nature Communications · 143 citations
https://doi.org/10.1038/s41467-020-16991-2
P
Paula Iruzubieta
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
218
Papers
3.3K
Citations
31
h-index
63
i10-index
Paula Iruzubieta is an academic researcher from Marqués de Valdecilla University Hospital. The author has contributed to research in topics: Liver Disease Diagnosis and Treatment & Diet, Metabolism, and Disease & Liver Disease and Transplantation. The author has an h-index of 31, co-authored 186 publications.
ORCID: 0000-0001-9476-1801Papers by this author
worksA global research priority agenda to advance public health responses to fatty liver disease
2023 · Journal of Hepatology · 122 citations
https://doi.org/10.1016/j.jhep.2023.04.035
Measurement and clinical usefulness of bilirubin in liver disease
2021 · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · 121 citations
https://doi.org/10.1515/almed-2021-0047
The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury
2017 · Nature Communications · 107 citations
https://doi.org/10.1038/s41467-017-01970-x
Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis
2022 · Journal of Hepatology · 100 citations
https://doi.org/10.1016/j.jhep.2022.02.003
miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease
2019 · Molecular Metabolism · 47 citations
https://doi.org/10.1016/j.molmet.2019.08.008
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat